| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
American Journal of Pathology, Vol 148, 189-200, Copyright © 1996 by American Society for Investigative Pathology
REGULAR ARTICLES |
K Hashimoto, T Tsujimura, Y Moriyama, A Yamatodani, M Kimura, K Tohya, M Morimoto, H Kitayama, Y Kanakura and Y Kitamura
Department of Pathology, Faculty of Medicine, Osaka University, Suita, Japan.
Two mutations of c-kit receptor tyrosine kinase (KIT), valine-559 to glycine (G559) and aspartic acid-814 to valine (V814), resulted in its constitutive activation. To examine the transforming and differentiation-inducing potential of the mutant KIT, we used the murine interleukin-3-dependent IC-2 mast cell line as a transfectant. The IC-2 cells contained few basophilic granules and did not express KIT on the surface. The KITG559 or KITV814 gene was introduced into IC- 2 cells using a retroviral vector. KITG559 and KITV814 expressed in IC- 2 cells were constitutively phosphorylated on tyrosine and demonstrated kinase activity in the absence of stem cell factor, which is a ligand for KIT. IC-2 cells expressing either KITG559 or KITV814 (IC-2G559 or IC-2V814 cells) showed factor-independent growth in suspension culture and produced tumors in nude athymic mice. In addition, IC-2G559 and IC- 2V814 cells showed a more mature phenotype compared with the phenotype of the original IC-2 cells, especially after transplantation into nude mice. The number of basophilic granules and the content of histamine increased remarkably. KITG559 and KITV814 also influenced the transcriptional phenotype of mouse mast cell proteases (MMCP) in IC-2 cells. The expression of MMCP-2, MMCP-4, and MMCP-6 was much greater in IC-2G559 and IC-2V814 cells than in the original IC-2 cells. The results indicated that constitutively activated KIT had not only oncogenic activity but also differentiation-inducing activity in mast cells.
This article has been cited by other articles:
 |
|
 |
|
  V. Munugalavadla, E. C. Sims, J. Borneo, R. J. Chan, and R. Kapur Genetic and pharmacologic evidence implicating the p85{alpha}, but not p85{beta}, regulatory subunit of PI3K and Rac2 GTPase in regulating oncogenic KIT-induced transformation in acute myeloid leukemia and systemic mastocytosis Blood, September 1, 2007; 110(5): 1612 - 1620. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Furuno, A. Ito, Y.-i. Koma, K. Watabe, H. Yokozaki, J. Bienenstock, M. Nakanishi, and Y. Kitamura The Spermatogenic Ig Superfamily/Synaptic Cell Adhesion Molecule Mast-Cell Adhesion Molecule Promotes Interaction with Nerves J. Immunol., June 1, 2005; 174(11): 6934 - 6942. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Tanaka, M. Konno, S. Muto, N. Kambe, E. Morii, T. Nakahata, A. Itai, and H. Matsuda A novel NF-{kappa}B inhibitor, IMD-0354, suppresses neoplastic proliferation of human mast cells with constitutively activated c-kit receptors Blood, March 15, 2005; 105(6): 2324 - 2331. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Jelacic and D. Linnekin PKC{delta} plays opposite roles in growth mediated by wild-type Kit and an oncogenic Kit mutant Blood, March 1, 2005; 105(5): 1923 - 1929. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Lennartsson, T. Jelacic, D. Linnekin, and R. Shivakrupa Normal and Oncogenic Forms of the Receptor Tyrosine Kinase Kit Stem Cells, January 1, 2005; 23(1): 16 - 43. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. L. Taylor, D. Sehgal, M. Raffeld, H. Obiakor, C. Akin, R. G. Mage, and D. D. Metcalfe Demonstration That Mast Cells, T Cells, and B Cells Bearing the Activating Kit Mutation D816V Occur in Clusters within the Marrow of Patients with Mastocytosis J. Mol. Diagn., November 1, 2004; 6(4): 335 - 342. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Shivakrupa, A. Bernstein, N. Watring, and D. Linnekin Phosphatidylinositol 3'-Kinase Is Required for Growth of Mast Cells Expressing the Kit Catalytic Domain Mutant Cancer Res., August 1, 2003; 63(15): 4412 - 4419. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Frost, P. T. Ferrao, T. P. Hughes, and L. K. Ashman Juxtamembrane Mutant V560GKit Is More Sensitive to Imatinib (STI571) Compared with Wild-Type c-Kit Whereas the Kinase Domain Mutant D816VKit Is Resistant Mol. Cancer Ther., October 1, 2002; 1(12): 1115 - 1124. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Ueda, M. Mizuki, H. Ikeda, T. Tsujimura, I. Matsumura, K. Nakano, H. Daino, Z.-i. Honda, J. Sonoyama, H. Shibayama, et al. Critical roles of c-Kit tyrosine residues 567 and 719 in stem cell factor-induced chemotaxis: contribution of src family kinase and PI3-kinase on calcium mobilization and cell migration Blood, May 1, 2002; 99(9): 3342 - 3349. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. L. Taylor, J. Dastych, D. Sehgal, M. Sundstrom, G. Nilsson, C. Akin, R. G. Mage, and D. D. Metcalfe The Kit-activating mutation D816V enhances stem cell factor-dependent chemotaxis Blood, August 15, 2001; 98(4): 1195 - 1199. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z.-Q. Ning, J. Li, and R. J. Arceci Signal transducer and activator of transcription 3 activation is required for Asp816 mutant c-Kit-mediated cytokine-independent survival and proliferation in human leukemia cells Blood, June 1, 2001; 97(11): 3559 - 3567. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Hongyo, T. Li, M. Syaifudin, R. Baskar, H. Ikeda, Y. Kanakura, K. Aozasa, and T. Nomura Specific c-kit Mutations in Sinonasal Natural Killer/T-Cell Lymphoma in China and Japan Cancer Res., May 1, 2000; 60(9): 2345 - 2347. [Abstract] [Full Text]
|
|
|
|
|
|
A. Beghini, P. Peterlongo, C. B. Ripamonti, L. Larizza, R. Cairoli, E. Morra, and C. Mecucci C-kit mutations in core binding factor leukemias Blood, January 15, 2000; 95(2): 726 - 728. [Full Text] [PDF]
|
|
|
|
|
|
A. Tanaka, K. Arai, Y. Kitamura, and H. Matsuda Matrix Metalloproteinase-9 Production, a Newly Identified Function of Mast Cell Progenitors, Is Downregulated by c-kit Receptor Activation Blood, October 1, 1999; 94(7): 2390 - 2395. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Jippo, Y.-M. Lee, Y. Katsu, K. Tsujino, E. Morii, D.-K. Kim, H.-M. Kim, and Y. Kitamura Deficient Transcription of Mouse Mast Cell Protease 4 Gene in Mutant Mice of mi/mi Genotype Blood, March 15, 1999; 93(6): 1942 - 1950. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. J. Longley Jr., D. D. Metcalfe, M. Tharp, X. Wang, L. Tyrrell, S.-z. Lu, D. Heitjan, and Y. Ma Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis PNAS, February 16, 1999; 96(4): 1609 - 1614. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Ito, E. Morii, D.-K. Kim, T. R. Kataoka, T. Jippo, K. Maeyama, H. Nojima, and Y. Kitamura Inhibitory Effect of the Transcription Factor Encoded by the mi Mutant Allele in Cultured Mast Cells of Mice Blood, February 15, 1999; 93(4): 1189 - 1196. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Tsujimura, K. Hashimoto, H. Kitayama, H. Ikeda, H. Sugahara, I. Matsumura, T. Kaisho, N. Terada, Y. Kitamura, and Y. Kanakura Activating Mutation in the Catalytic Domain of c-kit Elicits Hematopoietic Transformation by Receptor Self-Association Not at the Ligand-Induced Dimerization Site Blood, February 15, 1999; 93(4): 1319 - 1329. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Kunisada, S.-Z. Lu, H. Yoshida, S. Nishikawa, S.-i. Nishikawa, M. Mizoguchi, S.-i. Hayashi, L. Tyrrell, D. A. Williams, X. Wang, et al. Murine Cutaneous Mastocytosis and Epidermal Melanocytosis Induced by Keratinocyte Expression of Transgenic Stem Cell Factor J. Exp. Med., May 18, 1998; 187(10): 1565 - 1573. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Ferrao, T. J. Gonda, and L. K. Ashman Expression of Constitutively Activated Human c-Kit in Myb Transformed Early Myeloid Cells Leads to Factor Independence, Histiocytic Differentiation, and Tumorigenicity Blood, December 1, 1997; 90(11): 4539 - 4552. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. C. Broudy Stem Cell Factor and Hematopoiesis Blood, August 15, 1997; 90(4): 1345 - 1364. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
